Detail akcie Cara Therap Rg online

Business Summary: Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tvardi Therapeutics Inc revenues decreased 18% to $2.6M. Net loss decreased 89% to $6.3M. Revenues reflect Other revenue segment decrease of 54% to $1.3M, Collaborative revenue segment decrease of 43% to $1.2M. Lower net loss reflects Research and development - Balancing decrease of 99% to $319K (expense), Other Income increase from $3.9M (expense) to $9.8M (income).